| 03/08/26 | 13:00:00 | 3 Aug 2026 | | Laboratory Expansion to Accelerate Sales in USA | RNS |
| 22/07/26 | 12:00:00 | 22 Jul 2026 | | Update on Sales in USA | RNS |
| 15/07/26 | 07:00:05 | 15 Jul 2026 | | Half Year Operational Update | RNS |
| 30/06/26 | 07:00:07 | 30 Jun 2026 | | Change of Corporate Broker | RNS |
| 16/06/26 | 12:33:17 | 16 Jun 2026 | | Result of AGM | RNS |
| 16/06/26 | 07:00:08 | 16 Jun 2026 | | CIZ1B Test Approved For Clinical Use in USA | RNS |
| 12/06/26 | 07:00:06 | 12 Jun 2026 | | Patent Granted in USA | RNS |
| 21/05/26 | 07:51:13 | 21 May 2026 | | Notice of AGM | RNS |
| 07/05/26 | 07:00:08 | 7 May 2026 | | Issue of Options, Salary Waivers, Incentive Plan | RNS |
| 06/05/26 | 07:00:03 | 6 May 2026 | | Conversion of Convertible Loan Notes | RNS |
| 30/04/26 | 07:00:06 | 30 Apr 2026 | | Final results for the year ended 31 December 2025 | RNS |
| 02/04/26 | 07:00:03 | 2 Apr 2026 | | £250,000 Funding Facility | RNS |
| 23/02/26 | 07:00:10 | 23 Feb 2026 | | Progress on Launch of Biomarker Test in USA | RNS |
| 04/02/26 | 07:00:09 | 4 Feb 2026 | | Patent Granted in Canada | RNS |
| 05/11/25 | 07:01:01 | 5 Nov 2025 | | £250,000 Convertible Loan Note Issue | RNS |
| 05/11/25 | 07:00:09 | 5 Nov 2025 | | LOI with leading UK Clinical Diagnostic Group | RNS |
| 27/10/25 | 11:32:31 | 27 Oct 2025 | | Change of Registered Office | RNS |
| 30/09/25 | 07:00:11 | 30 Sept 2025 | | Interim Results | RNS |
| 29/09/25 | 07:00:06 | 29 Sept 2025 | | Update on Clinical Laboratory Partnerships in USA | RNS |
| 18/08/25 | 07:00:07 | 18 Aug 2025 | | Commercial Progress in USA | RNS |
| 30/06/25 | 13:45:50 | 30 Jun 2025 | | Result of AGM | RNS |
| 06/06/25 | 11:00:00 | 6 Jun 2025 | | Notice of AGM | RNS |
| 28/05/25 | 07:00:06 | 28 May 2025 | | Holding(s) in Company | RNS |
| 20/05/25 | 07:00:03 | 20 May 2025 | | £150,000 Convertible Loan Note Issue | RNS |
| 30/04/25 | 11:18:56 | 30 Apr 2025 | | Final results for the year ended 31 December 2024 | RNS |
| 28/04/25 | 07:00:07 | 28 Apr 2025 | | Contract in Caribbean and Update on CIZ1B | RNS |
| 14/04/25 | 10:00:00 | 14 Apr 2025 | | Launch of New Website | RNS |
| 25/03/25 | 07:00:14 | 25 Mar 2025 | | Appointment of Non-Executive Director | RNS |
| 24/03/25 | 07:00:08 | 24 Mar 2025 | | Update on Launch of CIZ1B Biomarker Assay | RNS |
| 02/01/25 | 07:00:05 | 2 Jan 2025 | | Appointment of Professor Dawn Coverley as CSO | RNS |
| 16/12/24 | 07:00:04 | 16 Dec 2024 | | Update on Strategic Partnership in North America | RNS |
| 21/10/24 | 07:00:04 | 21 Oct 2024 | | Execution of Agreement for North America | RNS |
| 03/10/24 | 13:12:12 | 3 Oct 2024 | | Update on Licensing and Partnership Agreement | RNS |
| 30/09/24 | 07:00:11 | 30 Sept 2024 | | Interim Results | RNS |
| 16/09/24 | 07:00:08 | 16 Sept 2024 | | Holding(s) in Company | RNS |
| 09/09/24 | 07:00:07 | 9 Sept 2024 | | Collaboration with Moffitt Cancer Center | RNS |
| 25/07/24 | 07:00:07 | 25 Jul 2024 | | Update on Strategic Partnership in North America | RNS |
| 18/07/24 | 07:00:05 | 18 Jul 2024 | | Manufacturing Agreement with BBI Solutions | RNS |
| 09/07/24 | 07:00:08 | 9 Jul 2024 | | Issue of Share Options in Lieu of Consultancy Fees | RNS |
| 24/06/24 | 12:42:30 | 24 Jun 2024 | | Result of AGM | RNS |
| 17/06/24 | 07:00:08 | 17 Jun 2024 | | Update on North American Strategic Licensing MoU | RNS |
| 03/06/24 | 07:00:12 | 3 Jun 2024 | | Notice of Annual General Meeting | RNS |
| 13/05/24 | 07:00:10 | 13 May 2024 | | Holding(s) in Company | RNS |
| 30/04/24 | 17:00:00 | 30 Apr 2024 | | Total Voting Rights | RNS |
| 30/04/24 | 09:12:03 | 30 Apr 2024 | | Final results for the year ended 31 December 2023 | RNS |
| 23/04/24 | 11:20:06 | 23 Apr 2024 | | Holding(s) in Company | RNS |
| 02/04/24 | 07:00:11 | 2 Apr 2024 | | Licensing and Partnership MoU for North America | RNS |
| 26/03/24 | 07:00:07 | 26 Mar 2024 | | Placing to raise £0.62 million | RNS |
| 28/09/23 | 07:00:10 | 28 Sept 2023 | | Interim Results | RNS |
| 21/09/23 | 07:00:07 | 21 Sept 2023 | | Update on Put Option with Conduit | RNS |
